Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity hikes target price on XPS Pensions

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on financial services business XPS Pensions from 435.0p to 459.0p on Thursday following "another year of impressive double-digit growth" in all key financial metrics in FY25. XPS reported an 18% year-on-year jump in total revenues to £231.8m, a 27% increase in adjusted underlying earnings to £69.7m and a 22 basis point increase in adjusted EBITDA margins to 30.1%.

Following XPS' Thursday morning earnings, Canaccord Genuity said its forecasts had been tweaked, with a 1% uplift to revenue in FY26 and FY27, also resulting in a similar upgrade to adjusted earnings per share.

"In our opinion, XPS is a very well-managed business with a strong culture, high client retention, and multiple significant revenue opportunities, all of which should continue to support at least mid-single-digit percentage organic revenue growth in the medium term," said the Canadian bank, which reiterated its 'buy' rating on the stock.

"The defensive, regulatory-driven characteristics of the revenue model, while delivering operating leverage, remains very much a key attraction, in our view."

Canaccord Genuity noted that when arriving at its target price, it had taken the peer group's one-year forward price-to-earnings ratio of 20.5x and applied it to its CY26 EPS forecast. It also said its new target price implied a 22% upside and a total shareholder return of 26%.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.